HKD96.25
0.68% today
Hong Kong, Sep 16, 10:09 am CET
ISIN
KYG4818G1010
Symbol
1801

Innovent Biologics Stock price

HKD96.25
-5.65 5.54% 1M
+56.20 140.32% 6M
+59.65 162.98% YTD
+52.05 117.76% 1Y
+69.10 254.51% 3Y
+32.05 49.92% 5Y
+79.67 480.52% 10Y
+79.67 480.52% 20Y
Hong Kong, Closing price Tue, Sep 16 2025
+0.65 0.68%
ISIN
KYG4818G1010
Symbol
1801
Industry

Key metrics

Basic
Market capitalization
HKD167.6b
Enterprise Value
HKD160.9b
Net debt
positive
Cash
HKD10.4b
Shares outstanding
1.7b
Valuation (TTM | estimate)
P/E
129.2 | 332.1
P/S
13.4 | 12.4
EV/Sales
12.9 | 11.9
EV/FCF
-
P/B
10.6
Financial Health
Equity Ratio
60.7%
Return on Equity
-0.7%
ROCE
7.4%
ROIC
12.6%
Debt/Equity
0.2
Financials (TTM | estimate)
Revenue
HKD12.5b | HKD13.6b
EBITDA
- | HKD862.1m
EBIT
HKD1.5b | HKD516.0m
Net Income
HKD1.2b | HKD476.0m
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
53.2% | 31.7%
EBITDA
- | 111.7%
EBIT
224.4% | 1,101.2%
Net Income
188.4% | 560.3%
Free Cash Flow
-
Margin (TTM | estimate)
Gross
85.4%
EBITDA
- | 6.4%
EBIT
12.0%
Net
9.9% | 3.5%
Free Cash Flow
-
More
EPS
HKD0.7
FCF per Share
-
Short interest
-
Employees
6k
Rev per Employee
HKD1.8m
Show more

Is Innovent Biologics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,016 stocks worldwide.

Innovent Biologics Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a Innovent Biologics forecast:

29x Buy
88%
4x Hold
12%

Analyst Opinions

33 Analysts have issued a Innovent Biologics forecast:

Buy
88%
Hold
12%

Financial data from Innovent Biologics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
12,482 12,482
53% 53%
100%
- Direct Costs 1,821 1,821
27% 27%
15%
10,662 10,662
59% 59%
85%
- Selling and Administrative Expenses 6,232 6,232
32% 32%
50%
- Research and Development Expense 2,503 2,503
15% 15%
20%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,493 1,493
224% 224%
12%
Net Profit 1,237 1,237
188% 188%
10%

In millions HKD.

Don't miss a Thing! We will send you all news about Innovent Biologics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Innovent Biologics, Inc. is a biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases. The company is headquartered in Suzhou, Jiangsu and currently employs 5,659 full-time employees. The company went IPO on 2018-10-31. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The firm mainly operates in the domestic and overseas markets.

Head office China
Employees 5,659
Website www.innoventbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today